Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complet...

Full description

Bibliographic Details
Authors: Nagler, Arnon, Labopin, Mriam, Blaise, Didier, Raiola, Anna Maria, López Corral, Lucia, Bramanti, Stefania, Sica, Simona, Kwon, Mi, Koc, Yener, Pavlu, Jiri, Kulagin, Alexander, Busca, Alessandro, Bermúdez Rodríguez, María Aranzazu, Reményi, Péter, Schmind, Christoph, Brissot, Eolia, Sanz, Jaime, Bazarbachi, Ali, Giebel, Sebastian, Ciceri, Fabio
Format: article
Publication Date:2023
Country:España
Institution:Universidad de Cantabria (UC)
Repository:UCrea Repositorio Abierto de la Universidad de Cantabria
Language:English
OAI Identifier:oai:repositorio.unican.es:10902/30258
Online Access:https://hdl.handle.net/10902/30258
Access Level:Open access
Keyword:Haploidentical allogeneic stem cell transplantation
Post-transplantation cyclophosphamide
Secondary acute myeloid leukemia
De novo acute myeloid leukemia
Transplantation outcomes
id ES_e81a341c7adaddd1caa4aa9c99cecfaa
oai_identifier_str oai:repositorio.unican.es:10902/30258
network_acronym_str ES
network_name_str España
repository_id_str
spelling Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMTNagler, ArnonLabopin, MriamBlaise, DidierRaiola, Anna MariaLópez Corral, LuciaBramanti, StefaniaSica, SimonaKwon, MiKoc, YenerPavlu, JiriKulagin, AlexanderBusca, AlessandroBermúdez Rodríguez, María AranzazuReményi, PéterSchmind, ChristophBrissot, EoliaSanz, JaimeBazarbachi, AliGiebel, SebastianCiceri, FabioHaploidentical allogeneic stem cell transplantationPost-transplantation cyclophosphamideSecondary acute myeloid leukemiaDe novo acute myeloid leukemiaTransplantation outcomesWe compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8 years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) 3 21.3% versus 40.8%, p < 0.0001 and Karnofsky performance status (KPS) with KPS - 90 in 78% versus 68.5%, respectively, p = 0.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9 months, respectively, p = 0.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, p < 0.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR) = 0.98, p = 0.9 and 23.4% versus 20.6%, HR = 0.92, p = 0.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR = 0.95, p = 0.67; 61.4% versus 66.4%, HR = 0.91, p = 0.51 and 46.3% versus 48.2%, HR = 0.92, p = 0.48, respectively. Similarly, the incidence of engraftment as well as acute and chronic GVHD was similar between the 2 cohorts. In conclusion, HaploSCT with PTCy may be able to overcome the bad prognosis of sAML as results are not significantly different to those of HaploSCT in de novo AMLBiomed CentralUniversidad de Cantabria20232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/30258Journal of Hematology & Oncology, 2023, 16, 58reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/302582026-06-02T12:39:31Z
dc.title.none.fl_str_mv Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
title Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
spellingShingle Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Nagler, Arnon
Haploidentical allogeneic stem cell transplantation
Post-transplantation cyclophosphamide
Secondary acute myeloid leukemia
De novo acute myeloid leukemia
Transplantation outcomes
title_short Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
title_full Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
title_fullStr Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
title_full_unstemmed Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
title_sort Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
dc.creator.none.fl_str_mv Nagler, Arnon
Labopin, Mriam
Blaise, Didier
Raiola, Anna Maria
López Corral, Lucia
Bramanti, Stefania
Sica, Simona
Kwon, Mi
Koc, Yener
Pavlu, Jiri
Kulagin, Alexander
Busca, Alessandro
Bermúdez Rodríguez, María Aranzazu
Reményi, Péter
Schmind, Christoph
Brissot, Eolia
Sanz, Jaime
Bazarbachi, Ali
Giebel, Sebastian
Ciceri, Fabio
author Nagler, Arnon
author_facet Nagler, Arnon
Labopin, Mriam
Blaise, Didier
Raiola, Anna Maria
López Corral, Lucia
Bramanti, Stefania
Sica, Simona
Kwon, Mi
Koc, Yener
Pavlu, Jiri
Kulagin, Alexander
Busca, Alessandro
Bermúdez Rodríguez, María Aranzazu
Reményi, Péter
Schmind, Christoph
Brissot, Eolia
Sanz, Jaime
Bazarbachi, Ali
Giebel, Sebastian
Ciceri, Fabio
author_role author
author2 Labopin, Mriam
Blaise, Didier
Raiola, Anna Maria
López Corral, Lucia
Bramanti, Stefania
Sica, Simona
Kwon, Mi
Koc, Yener
Pavlu, Jiri
Kulagin, Alexander
Busca, Alessandro
Bermúdez Rodríguez, María Aranzazu
Reményi, Péter
Schmind, Christoph
Brissot, Eolia
Sanz, Jaime
Bazarbachi, Ali
Giebel, Sebastian
Ciceri, Fabio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Haploidentical allogeneic stem cell transplantation
Post-transplantation cyclophosphamide
Secondary acute myeloid leukemia
De novo acute myeloid leukemia
Transplantation outcomes
topic Haploidentical allogeneic stem cell transplantation
Post-transplantation cyclophosphamide
Secondary acute myeloid leukemia
De novo acute myeloid leukemia
Transplantation outcomes
description We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide (PTCy). Seventeen hundred and eleven AML patients (sAML-231, de novo-1480) in first complete remission transplanted from 2010 to 2021, were included. Patients with de novo AML were younger, median age 55.8 versus 60.8 years, p < 0.0001, had better transplantation comorbidity index (HCT-CI) 3 21.3% versus 40.8%, p < 0.0001 and Karnofsky performance status (KPS) with KPS - 90 in 78% versus 68.5%, respectively, p = 0.002. The two patient groups did not differ with respect to gender, cytomegalovirus serostatus, and cell source. Median time from diagnosis to HaploSCT was 5.2 versus 4.9 months, respectively, p = 0.005. Fewer sAML patients received myeloablative conditioning 35.1% versus 50.1%, p < 0.0001. Two hundred and eleven sAML and 410 de novo AML patients were included in the matched-pair analysis matching two de novo AML with each sAML. No significant difference was observed in any transplantation outcome parameter between the sAML versus de novo AML groups. Two-year non-relapse mortality and relapse incidence did not differ with HaploSCT for de novo versus sAML; 21.4% versus 21%, hazard ratio (HR) = 0.98, p = 0.9 and 23.4% versus 20.6%, HR = 0.92, p = 0.67, respectively. Two-year leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, relapse-free survival were also not different between the de novo AML and sAML groups 55.2% versus 58.4%, HR = 0.95, p = 0.67; 61.4% versus 66.4%, HR = 0.91, p = 0.51 and 46.3% versus 48.2%, HR = 0.92, p = 0.48, respectively. Similarly, the incidence of engraftment as well as acute and chronic GVHD was similar between the 2 cohorts. In conclusion, HaploSCT with PTCy may be able to overcome the bad prognosis of sAML as results are not significantly different to those of HaploSCT in de novo AML
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/30258
url https://hdl.handle.net/10902/30258
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Biomed Central
publisher.none.fl_str_mv Biomed Central
dc.source.none.fl_str_mv Journal of Hematology & Oncology, 2023, 16, 58
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422912395542528
score 15.301603

Similar Items